Antibody-Drug Conjugates and Immunotoxins
Springer-Verlag New York Inc.
978-1-4614-5455-7 (ISBN)
Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins.- Antibody-Drug Conjugate Development.- Components of ADC Development: Assay Methodologies and Challenges.- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates.- Predictive Biomarkers for Antibody-Drug Conjugates.- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates.- Linker Technology and Impact of Linker Design on ADC Properties.- Antibody-drug conjugates for the treatment of B-cell malignancies.- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies.- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies.- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer.- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE).- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer.- EphA2 Immunoconjugate.- Anti-PSMA Antibody-Drug Conjugates.- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine.- Studies on the Metabolism of Antibody-Drug Conjugates.- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu.- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors.- Index.
| Erscheint lt. Verlag | 12.12.2012 |
|---|---|
| Reihe/Serie | Cancer Drug Discovery and Development |
| Zusatzinfo | X, 378 p. |
| Verlagsort | New York, NY |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Studium ► Querschnittsbereiche ► Infektiologie / Immunologie | |
| Schlagworte | antibodies • Conjugates • immunotoxins • therapeutics |
| ISBN-10 | 1-4614-5455-7 / 1461454557 |
| ISBN-13 | 978-1-4614-5455-7 / 9781461454557 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
